Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Key news from ADA 76th Scientific Sessions
- Part 1: cardiovascular benefits, combination treatments, Invokana weight loss benefits
- Part 2: long-acting insulins, effect of CV outcomes research on GLP-1s, DPP-4s, SGLT-2s
- David Kliff and Dr. George Bakris on EMPA-REG, the FDA, and the Future of SGLT-2s
Letter from the Editor
Most times when you get a Key Opinion Leader and well-known researcher like Dr. George Bakris to talk about trends in drugs, they want all the spotlight. In addition, they often won’t want anything to do with the business side of diabetes. However, due to the close relationship that our Publisher, Steve Freed, has with Dr. Bakris, he was able to get him together with David Kliff, the editor of Diabetic Investor, to talk about the SGLT-2 drugs and how they will affect both healthcare and the cost of healthcare. I am sure you will find this info fascinating, as the two of them offer their own perspectives on what this class of drugs means to the treatment of diabetes.
Announcements:
dLifeTV.com: Sunday, June 19, 7PM ET
From dLife.com: “Nat Strand talks food plans for a diabetes-friendly wedding; Chef Michel Nischan cooks up an Italian classic with a healthy twist — Zucchini Parmesan; Jim Turner takes the stage in Jim Turner’s Diabetes Theatre; Delaine Wright flies high on the trapeze with type 1 diabetes.” Sundays live online at dLifeTV.com at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at dLifeTV.com.
*****************************
We can make a difference!
*****************************
Dave Joffe, Editor-in-chief
This Week's Survey
Would you be interested in seeing the news briefings from the ADA meeting? Topics include beta-cell replacement, closed loop systems, CVD and diabetes, etc., and feature all the top doctors on each. They last about 45 minutes.
Follow the link to cast your vote!
In part 1 of our ADA Rundown, we look at cardiovascular benefits for multiple drugs, new combination treatments, and the possibility that Invokana’s weight loss benefits may also apply to people who don’t have diabetes.
Part 2 of our ADA Rundown checks out the latest information on competing long-acting insulins, and the ongoing research into potential class effect benefits for cardiovascular outcomes: as data shows CV benefits for DPP-4 and SGLT-2 treatments, are GLP-1 treatments under pressure?
David Kliff and Dr. George Bakris:
With so much breaking news surrounding SGLT-2 Inhibitors at ADA, what conclusions can we draw? Viewpoints from our guest editorialist David Kliff, and DIC advisory board member Dr. George Bakris.